PCSK9 Inhibitors

PCSK9 inhibitors are medicines that lower LDL, the "bad" cholesterol, and help prevent heart attacks and strokes. They are usually given as a shot under the skin every two weeks or once a month. They work by helping the liver pull more cholesterol out of the blood.

Medication

What people taking PCSK9 Inhibitors report

Every report comes from a Lived member, sent anonymously.

Have you tried PCSK9 Inhibitors for High Cholesterol (Hypercholesterolemia)?

NameHow it went

About PCSK9 Inhibitors

What It's For

PCSK9 inhibitors are prescription medicines that lower LDL (low-density lipoprotein) cholesterol, the so-called bad cholesterol that builds up in artery walls and drives heart attacks and strokes. They are usually added to a statin when LDL stays above the target a person's care team has set, and they can also help people with inherited high cholesterol, called familial hypercholesterolemia, whose levels stay high despite other treatment. Two injectable versions have been in use since 2015: evolocumab (Repatha) and alirocumab (Praluent). Both are approved to lower LDL cholesterol and to reduce the risk of heart attack, stroke and related heart events in adults at increased risk. In large trials of people who had already had heart disease, adding one of them to a statin lowered the chance of another event over two to three years, for example from about 11 in 100 people to about 9.5 in 100 after a recent heart attack or unstable angina. A 2025 trial found a similar benefit with evolocumab in people with narrowed arteries or diabetes who had not yet had a heart attack or stroke. Both are also approved for children with inherited high cholesterol, from age 10 for Repatha and age 8 for Praluent. Enlicitide (Lipfendra), approved in the US in 2026, is the first PCSK9 inhibitor taken as a daily pill. It is approved to lower LDL cholesterol in adults, but whether it prevents heart attacks and strokes is still being studied. Inclisiran (Leqvio) is a related medicine that targets the same protein in a different way and is given as an injection twice a year; it is also approved for LDL lowering, with heart outcome results still pending.

How It Works

LDL cholesterol is removed from the blood mainly by the liver. Liver cells carry LDL receptors on their surface, which catch LDL particles and pull them inside. PCSK9 (short for proprotein convertase subtilisin/kexin type 9) is a protein that attaches to these receptors and marks them for destruction, so the more PCSK9 there is, the fewer receptors are left to clear LDL. PCSK9 inhibitors block that protein. Repatha and Praluent are monoclonal antibodies, lab-made proteins that latch onto PCSK9 in the blood, and Lipfendra is a small ring-shaped molecule that binds it in a similar way. With PCSK9 out of the way, more receptors survive, the liver pulls more LDL out of circulation, and blood levels fall. Inclisiran works one step earlier: it tells liver cells to make less PCSK9 in the first place. Statins lower LDL partly by prompting the liver to make more of these receptors, which is why the two approaches add together. In a major trial, evolocumab added to a statin lowered LDL by about 60%, from a median of 92 mg/dL to 30 mg/dL. LDL is measured in milligrams per deciliter (mg/dL), and lower is better for people at high risk: current US guidelines aim for under 70 for many people with heart or artery disease and under 55 for those at the highest risk.

Dosage & Administration

Repatha and Praluent are injected under the skin of the abdomen, thigh or upper arm, usually by the person themselves or a caregiver after training, using a prefilled pen or syringe. Repatha is taken every two weeks or once a month; the monthly dose is given as three injections within 30 minutes. Praluent is taken every two or four weeks, and the dose can be raised if LDL does not fall enough. The pens are kept in the refrigerator and should be left out for about 30 to 40 minutes to reach room temperature before injecting. Repatha can be kept at room temperature for up to 30 days. Rotate injection sites and avoid skin that is bruised, red or tender. If an injection is missed by 7 days or less, take it and return to the usual schedule. If more time has passed, the instructions differ between the two-week and monthly schedules, so check the leaflet or ask the pharmacist. Lipfendra is one tablet a day, taken in the morning on an empty stomach with water, black coffee or plain tea. Swallow it whole without splitting, crushing or chewing, and wait at least 30 minutes before eating or drinking anything else, because food reduces how much of the medicine is absorbed. Leqvio is given by a health professional in a clinic: one injection to start, another at three months, and then one every six months.

Side Effects

Most people tolerate PCSK9 inhibitors well. With the injections, the most common problems are redness, pain or bruising where the needle went in, along with cold-like symptoms, flu-like illness and back or muscle aches; in trials these were only slightly more frequent than with placebo shots. With Lipfendra, side effects were similar to placebo overall, though diarrhea and dizziness were somewhat more common in one study. Allergic reactions can happen, ranging from rash or itching to rare serious reactions with swelling of the face, lips, tongue or throat (called angioedema). Swelling of the tongue or throat, or trouble breathing, needs emergency care right away. For a rash, hives or itching without those signs, stop the next dose and contact the prescriber promptly.

Interactions & Warnings

Anyone who has had a serious allergic reaction to one of these medicines should not take it again. Some Repatha pens and syringes have needle covers containing natural rubber latex, and latex-free versions are available, so mention a latex allergy to the prescriber or pharmacist. PCSK9 inhibitors have few known drug interactions, and Lipfendra can be taken alongside other medicines. Because they are almost always used together with a statin, side effects from the statin, such as muscle aches, are worth reporting rather than assuming they come from the newer drug. There is little information about these medicines in pregnancy. The antibody medicines cross the placenta, and the labels for Leqvio and Lipfendra advise stopping when pregnancy is recognized unless there is a strong reason to continue. Because high cholesterol damages arteries over many years, a pause during pregnancy usually has little long-term effect for most people, so anyone pregnant or planning pregnancy should discuss timing with the prescriber.

What to Expect

LDL starts falling within the first few weeks, and a blood test about four weeks after starting can show how well the medicine is working. With a once-monthly or every-four-week schedule, the test is best done just before the next dose, because levels can drift up toward the end of the interval. Many people reach LDL levels far lower than they managed on a statin alone. You will not feel the lower cholesterol, and the payoff is a reduced chance of a heart attack or stroke over years, not a change in day-to-day symptoms. The heart benefits seen in trials came from staying on treatment for years, so these medicines are generally meant as long-term treatment alongside a statin, diet and exercise. Cost and insurance are a real part of the experience. Insurers often require proof that LDL is still high on a statin, and sometimes on ezetimibe (an inexpensive cholesterol pill usually tried first as an add-on), before covering a PCSK9 inhibitor. Prior authorization paperwork and renewals are common, so it helps to know who on the care team handles them.

Questions to Ask Your Doctor

  1. 1.What LDL level are we aiming for, and how far is my current level from it?
  2. 2.Why a PCSK9 inhibitor for me rather than adding ezetimibe or another option first?
  3. 3.Would an injection every few weeks, a daily pill or a twice-yearly clinic shot suit me best, and do they differ in proven heart benefit?
  4. 4.What will my insurance require, and what happens if coverage is denied or lapses?
  5. 5.How long am I likely to stay on this, and how often will we check my cholesterol?

Last reviewed • Oct 2026

Educational content, not medical advice.